MedTrace Logo

500mg Fulvestrant in HR+ MBC

NCT03708432 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2024-02-26

No results posted yet for this study

Summary

To study the real world use of 500mg Fulvestrant in HR+ MBC.

Conditions

Sponsors & Collaborators

  • Fudan University

    lead OTHER

Principal Investigators

  • Biyun Wang, Professor · Fudan University

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-07-15
Primary Completion
2018-06-15
Completion
2018-08-15

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03708432 on ClinicalTrials.gov